Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by founding CEO Tassos Gianakakos and fellow former MyoKardia ...

AI, omics, and systems biology can now help scientists design targeted drugs for cardiovascular disease pathways once thought "untreatable." A new article published in Frontiers in Science says these ...

Medera announced that its wholly owned preclinical subsidiary for disease modelling and drug discovery, Novoheart, has entered into a partnership with Curi Bio. This strategic collaboration integrates ...

Researchers have developed a scalable bioreactor-based system to produce cardiac organoids that successfully integrated into ...

Cardiovascular disease remains a leading global health burden, yet many preclinical systems still struggle to predict how candidate drugs will perform in the human heart. Rodent models are limited by ...

A new mathematical method, validated with experimental animal data, provides a fast, reliable and minimally invasive way of determining how to treat critical blood pressure changes during surgery or ...

Recent advances in cardiovascular research increasingly recognize the gut microbiome as a pivotal factor influencing cardiovascular disease (CVD) pathogenesis and treatment outcomes. The intricate ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Cardiovascular disease can be managed with drugs that take various approaches, but few of them work by reducing inflammation. Novartis is getting an anti-inflammatory drug candidate through its $1.4 ...